Alpha 2.0
Login Register
» Authors » Avineesh Singh

Avineesh Singh

Explore the profile of Avineesh Singh including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 55
Followers 0
Related Specialties
Chemistry
Oncology
Pharmacology
Top 10 Co-Authors
Harish Rajak
Vijay K Patel
Ravichandran Veerasamy
Deepak K Jain
Preeti Patel
Deepak Kumar Jain
Prabodh Chander Sharma
Jageshwar
Murli Dhar Kharya
Bhupendra Singh Thakur
Published In
Curr Cancer Drug Targets
Cent Nerv Syst Agents Med Chem
Curr Pharm Des
Comb Chem High Throughput Screen
Curr Comput Aided Drug Des
Affiliations
Soon will be listed here.
Recent Articles
1.
Chromatographic Separation and Quantification of Nine Nitrosamine Genotoxic Impurities in a Single Method in Nebivolol Tablet by Using Validated Ultra-Sensitive Liquid Chromatography: Mass Spectrometry Analytical Method
Pathak M, Patel D, Kumar D, Singh A, Agrawal S
J Chromatogr Sci . 2024 Dec; 63(1. PMID: 39724937
N-nitrosamine impurities have been detected in a vast variety of drug substances and drug products, showing concern for regulatory aspects. To meet the regulatory requirement for the concerned impurity, a...
2.
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies
Patel P, Patel V, Singh A, Jawaid T, Kamal M, Rajak H
Curr Comput Aided Drug Des . 2018 May; 15(2):145-166. PMID: 29732991
Background: Overexpression of Histone deacetylase 1 (HDAC1) is responsible for carcinogenesis by promoting epigenetic silence of tumour suppressor genes. Thus, HDAC1 inhibitors have emerged as the potential therapeutic leads against...
3.
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies
Singh A, Patel P, Jageshwar , Patel V, Jain D, Kamal M, et al.
Curr Cancer Drug Targets . 2017 Jul; 18(8):720-736. PMID: 28669336
Histone deacetylase inhibitors (HDACi) have been demonstrated as an emerging class of anticancer drugs involved in regulation of gene expression and chromatin remodeling thus indicating valid targets for different types...
4.
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
Singh A, Patel V, Jain D, Patel P, Rajak H
Oncol Ther . 2017 Mar; 4(1):73-89. PMID: 28261641
The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid...
5.
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects
Singh A, Patel P, Patel V, Jain D, Veerasamy R, Sharma P, et al.
Curr Cancer Drug Targets . 2017 Jan; 17(5):456-466. PMID: 28067178
Background: Colorectal cancer is a devastating disease with a dismal prognosis which is heavily hampered by delayed diagnosis. Surgical resection, radiation therapy and chemotherapy are the curative options. Due to...
6.
Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents
Patel P, Singh A, Patel V, Jain D, Veerasamy R, Rajak H
Comb Chem High Throughput Screen . 2016 Aug; 19(9):735-751. PMID: 27487787
Background: Histone deacetylase (HDAC) inhibitors can reactivate gene expression and inhibit the growth and survival of cancer cells. Objective: To identify the important pharmacophoric features and correlate 3Dchemical structure with...
7.
Drug Design Strategies for the Discovery of Novel Anticonvulsants Concerned with Four Site Binding Pharmacophoric Model Studies
Jain D, Singh A, Patel V, Veerasamy R, Aggarwal N, Rajak H
Cent Nerv Syst Agents Med Chem . 2016 Apr; PMID: 27063392
Anticonvulsant refers to a group of pharmaceuticals used in the treatment of epileptic seizures. The use of current antiepileptic drugs has been questioned due to the non-selectivity of the drugs...
8.
Novel pyrimidine based semicarbazones: Confirmation of four binding site pharmacophoric model hypothesis for antiepileptic activity
Rajak H, Jain D, Singh S, Singh A, Patel V, Veerasamy R, et al.
Cent Nerv Syst Agents Med Chem . 2016 Mar; PMID: 27026153
Background: Epilepsy is a neurological disorder, characterized by seizures accompanied by loss or disturbance of consciousness affecting various physical and mental functions. Current anticonvulsant drugs are effective in controlling seizures...
9.
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity
Rajak H, Singh Thakur B, Singh A, Raghuvanshi K, Sah A, Veerasamy R, et al.
Bioorg Med Chem Lett . 2012 Dec; 23(3):864-8. PMID: 23265873
Two novel series of N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(2-methyl-5-(prop-1-en-2-yl)cyclohex-2-enylidene)semicarbazide and N(4)-(5-(2/3/4-substituted-phenyl)-1,3,4-oxadiazol-2-yl)-N(1)-(3,7-dimethylocta-3,6-dienylidene)-semicarbazide were synthesized to meet structural prerequisite indispensable for anticonvulsant activity. The anticonvulsant activities of the compounds were investigated using maximal electroshock seizure (MES),...
10.
Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers
Rajak H, Dewangan P, Patel V, Jain D, Singh A, Veerasamy R, et al.
Curr Pharm Des . 2012 Dec; 19(10):1923-55. PMID: 23237054
Tubulin protein is a highly imperative and feasible goal for anticancer drug discovery. Hundreds of naturally occurring, semi synthetic and synthetic antitubulin agents have been reported till now. Among these,...